Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis.
To establish human renal cell carcinoma (RCC) xenografts for preclinical studies, 55 renal tumors (33 primary and 22 metastatic lesions) were transplanted subcutaneously into severe combined immunodeficient mice. Twenty of 49 evaluable tumors (40.8%) grew with a median latency period of 89 days (36 to 209 days) from the day of engraftment. Tumor growth was stabilized after the fifth passage with a median time between passages of 38 days (19 to 80 days). Tumorigenicity was correlated with the metastatic phenotype of the tumor (54% success rate, p = 0.007) and with reduced survival of patients. Despite a possible evolution of histological features and tumor grading, established RCC xenografts were comparable to parental tumors, as assessed by karyotype and DNA-ploidy analyses. Molecular cytogenetic analysis also revealed specific genetic alterations characterizing distinct RCC types that were constant in parental and corresponding xenografts. In addition, this xenograft model has permitted the selection of minor tumor subclones with a proliferative advantage and minimal overexpressed chromosomal regions. We conclude that severe combined immunodeficient mice are useful recipients for the establishment of long-term RCC xenografts that can be used as valuable tools to evaluate the activity of new therapeutic approaches and to study biological parameters determining in vivo aggressiveness of human RCC.
Angevin
E
E
Unité d'Immunothérapie, Institut Gustave-Roussy, Villejuif, France.
Glukhova
L
L
Pavon
C
C
Chassevent
A
A
Terrier-Lacombe
M J
MJ
Goguel
A F
AF
Bougaran
J
J
Ardouin
P
P
Court
B H
BH
Perrin
J L
JL
Vallancien
G
G
Triebel
F
F
Escudier
B
B
D000328:Adult; D000368:Aged; D000818:Animals; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D051379:Mice; D016513:Mice, SCID / Q000601:surgery*; D008875:Middle Aged; D009368:Neoplasm Transplantation; D011379:Prognosis; D016511:Severe Combined Immunodeficiency / Q000601:surgery*; D014183:Transplantation, Heterologous